Q1 Earnings Estimate for MLTX Issued By HC Wainwright

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of MoonLake Immunotherapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.81) for the quarter. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.62) EPS.

MLTX has been the subject of a number of other research reports. Needham & Company LLC increased their price objective on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a report on Thursday. Wedbush reissued an “outperform” rating and set a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. Finally, The Goldman Sachs Group cut their target price on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $83.20.

MoonLake Immunotherapeutics Trading Down 0.0 %

NASDAQ:MLTX opened at $41.76 on Friday. The company has a market cap of $2.67 billion, a P/E ratio of -32.37 and a beta of 1.28. MoonLake Immunotherapeutics has a twelve month low of $37.55 and a twelve month high of $58.26. The company’s 50-day moving average price is $46.70 and its 200-day moving average price is $48.94.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.09).

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MLTX. FMR LLC grew its stake in MoonLake Immunotherapeutics by 28.1% during the 4th quarter. FMR LLC now owns 6,341,391 shares of the company’s stock worth $343,386,000 after purchasing an additional 1,391,167 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its stake in shares of MoonLake Immunotherapeutics by 90.3% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company’s stock valued at $95,965,000 after buying an additional 840,731 shares during the period. Polar Capital Holdings Plc grew its position in shares of MoonLake Immunotherapeutics by 120.0% during the fourth quarter. Polar Capital Holdings Plc now owns 1,100,000 shares of the company’s stock worth $59,565,000 after buying an additional 600,000 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of MoonLake Immunotherapeutics by 12.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company’s stock worth $181,059,000 after buying an additional 363,394 shares during the period. Finally, Federated Hermes Inc. raised its holdings in MoonLake Immunotherapeutics by 13.2% in the fourth quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company’s stock valued at $69,315,000 after acquiring an additional 149,724 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.